Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders

 
 

MIRENCO INC (MREO) Add to portfolio

1m | 3m | 6m | 1y | 2y | 5y | 10y
Price: $1.60 Metrics
OS: 32.0 M
Market cap: $51.2 M
Net debt: $258.8 k
EV: $51.4 M

 
TTM Valuation
EBITDA ($368.5) k
EBIT ($399.0) k
EPS

Recent News + Filings   (All items)
Date FiledTypeDescription
04/08/2021 GN Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
03/31/2021 GN Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
02/18/2021 GN Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
02/12/2021 GN Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additi...
02/10/2021 GN Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares
12/15/2020 GN Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank ...
11/23/2020 GN Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development


Financial Summary   (All financials)
In millions, except per share itemsDec-31-10Dec-31-09Dec-31-08Dec-31-07
Revenues0.40.30.8 
            Revenue growth31.4%-60.2%  
Cost of goods sold0.30.30.4 
Gross profit0.10.10.4 
            Gross margin25.3%23.7%51.6% 
Sales and marketing0.00.00.0 
General and administrative0.20.20.2 
EBIT-0.4-0.5-0.3 
            EBIT margin-100.2%-162.2%-41.2% 
Pre-tax income-0.5-0.6-0.4 
Income taxes0.00.00.0 
            Tax rate0.0%0.0%0.0% 
Net income-0.5-0.6-0.4 
            Net margin-117.7%-171.8%-44.3% 
 
Diluted EPS ($0.02)($0.01) 
Shares outstanding (diluted) 31.528.2 
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy